Camptothecin analogues: studies from The Johns Hopkins Oncology Center
- 1 January 1994
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 34 (1) , S53-S57
- https://doi.org/10.1007/bf00684864
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.1994
- Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating FactorJNCI Journal of the National Cancer Institute, 1993
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Clinical trials with the topoisomerase I inhibitors.1992
- Effects of CPT‐11 in combination with other anti‐cancer agents in cultureInternational Journal of Cancer, 1992
- Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activityJournal of Medicinal Chemistry, 1991
- Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cellsEuropean Journal of Cancer and Clinical Oncology, 1990
- DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGSAnnual Review of Biochemistry, 1989
- ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells.Journal of Biological Chemistry, 1988
- Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2Journal of the American Chemical Society, 1966